ClinicalTrials.gg
CompletedNCT02016482Updated May 30, 2017Results posted

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

A Phase 3 interventional study of Adalimumab and Placebo in Nail Psoriasis and Plaque Psoriasis, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
217
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
20th of 48
217 · median 148
Started
2014
with 1 other
Phase 3
26 of 48
1 open now
Registered
29th of 48
by date
Lead sponsor
3 of 48
AbbVie

Among the 48 studies testing adalimumab in Psoriasis, this one is the 20th largest by enrollment, is one of 2 that started in 2014, is one of 26 in phase 3, and was the 29th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.

03

Conditions studied

  • Nail Psoriasis
  • Plaque Psoriasis

Browse trials for

Keywords

  • Nail Psoriasis
  • Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have body surface area (BSA) ≥ 10% and a target fingernail Modified Nail Psoriasis Severity Index (mNAPSI) ≥ 8 at Week 0, OR BSA ≥ 5%, a target fingernail mNAPSI ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0.
  • Subject must have a Nail Psoriasis Physical Functioning Severity score of > 3, OR a Nail Psoriasis Pain Numeric Rating Scale (NRS) score of >3.
  • Subjects must have a Physician's Global Assessment (PGA) of Fingernail Psoriasis and a PGA of Skin Psoriasis of at least moderate.
  • Subject must have discontinued use of all systemic therapies for the treatment of psoriasis, or systemic therapies known to improve psoriasis for at least 4 weeks prior to Week 0, ustekinumab must have been discontinued at least 12 weeks prior to Week 0.
  • Target fingernail must have mNAPSI score of ≥ 8.
  • Adult subjects with clinical diagnosis of chronic plaque psoriasis (with disease duration of at least 6 months).

Exclusion criteria

Exclusion Criteria:

  • Prior adalimumab therapy.
  • Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis.
  • Recent infection requiring treatment.
  • Significant medical events or conditions that may put patients at risk for participation, including recent history of drug or alcohol abuse.
  • Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study.
  • History of cancer, except successfully treated skin cancer.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
217 participants (actual)

Study arms

  • Active comparator
    Adalimumab (ADA)

    Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.

    Biological: Adalimumab · Other: Placebo

  • Placebo comparator
    Placebo

    Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.

    Biological: Adalimumab · Other: Placebo

Interventions

  • BiologicalAdalimumab

    Also known as: ABT-D2E7, Humira

  • OtherPlacebo
06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26

    Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.

    Time frame: Week 26

  2. For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26

    The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.

    Time frame: Week 26

Secondary outcomes

  1. Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26

    Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  2. Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26

    Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Week 26

  3. Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26

    An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 26

  4. Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

    Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 26

  5. Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26

    The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.

    Time frame: Baseline, Week 26

  6. Percentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 26

    The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail bed component of "moderate" or "worse."

    Time frame: Week 26

  7. Percentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 26

    The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail matrix component of "moderate" or "worse."

    Time frame: Week 26

  8. Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26

    The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Week 26

  9. Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26

    The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Week 26

  10. Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26

    Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Week 26

  11. Change From Baseline in Target Fingernail mNAPSI Score at Week 26

    The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  12. Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26

    The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  13. Change From Baseline in Total Fingernail mNAPSI Score at Week 26

    Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  14. Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26

    Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  15. Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26

    Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Week 26

  16. Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26

    The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Week 26

  17. Change From Baseline in Target Fingernail NAPSI Score at Week 26

    The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  18. Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26

    The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  19. Change From Baseline in Total Fingernail NAPSI Score at Week 26

    Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

    Time frame: Baseline, Week 26

  20. Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

    Time frame: Baseline, Week 26

  21. Percent Change From Baseline in PASI Score at Week 26

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

    Time frame: Baseline, Week 26

  22. Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.

    Time frame: Week 26

  23. Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 26

    The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.

    Time frame: Week 26

  24. Percentage of Participants Achieving PGA-S of "Clear" at Week 26

    The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) with at least a 2-grade improvement relative to Baseline at Week 26.

    Time frame: Week 26

  25. Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26

    The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.

    Time frame: Week 26

  26. Change From Baseline in Total Body Surface Area (BSA) at Week 26

    BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

    Time frame: Baseline, Week 26

  27. Percent Change From Baseline in Total BSA at Week 26

    BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

    Time frame: Baseline, Week 26

  28. Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26

    An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 26

  29. Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

    Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 26

  30. Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26

    Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

    Time frame: Baseline, Week 26

  31. Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26

    Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

    Time frame: Baseline, Week 26

  32. Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26

    Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.

    Time frame: Baseline, Week 26

  33. Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26

    Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.

    Time frame: Week 26

  34. Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26

    The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating "fingernail psoriasis had no effect on this" and 10 indicating "fingernail psoriasis completely prevented me from this." A decrease in the WPAI:NPSO score indicates improvement.

    Time frame: Baseline, Week 26

  35. Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26

    The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.

    Time frame: Baseline, Week 26

  36. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26

    The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.

    Time frame: Baseline, Week 26

  37. Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26

    Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.

    Time frame: Baseline, Week 26

  38. Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study

    The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.

    Time frame: up to Week 26

  39. Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26

    Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 26

07

Results

Posted Feb 13, 2017
Limitations and caveats
Due to study design, a high percentage of participants randomized to the placebo arm early escaped from Period A and thus participated for a shorter duration than did participants in the active treatment arm.

Participant flow

Period A
Participant flow — Period A
MilestonePlaceboAdalimumab EOW
Started108109
Completed9494
Not completed1415
Withdrew: Adverse event35
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up33
Withdrew: Lack of efficacy21
Withdrew: Other30
Withdrew: Protocol violation01
Withdrew: Required alternative/prohibited therapy01
Period B
Participant flow — Period B
MilestonePlaceboAdalimumab EOW
Started9494
Completed8187
Not completed137
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up20
Withdrew: Lack of efficacy64
Withdrew: Other40
Withdrew: Required alternative/prohibited therapy02

Outcome measures

PrimaryPercentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement. The mNAPSI 75 response is defined as at least 75% reduction from baseline in mNAPSI.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 263.446.6
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 43.2 · 95% CI 32.8 to 53.6
PrimaryFor United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a PGA-F overall global score that met the definition of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame:
Week 26
Reported as:
Number · percentage of participants
For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26
percentage of participantsPlaceboAdalimumab EOW
For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 266.948.9
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 42.0 · 95% CI 30.8 to 53.2
SecondaryPercent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26-11.5 ± 3.19-56.2 ± 3.12
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean: -44.8 · 95% CI -53.5 to -36.0
SecondaryPercentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 260.06.6
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = 0.008 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 6.6 · 95% CI 1.8 to 11.3
SecondaryPercent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26

An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26-1.1 ± 0.24-3.7 ± 0.23
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean percent change: -2.6 · 95% CI -3.3 to -2.0
SecondaryChange From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-0.8 ± 0.24-3.7 ± 0.25
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -2.9 · 95% CI -3.6 to -2.2
SecondaryPercentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26

The range of possible scores was 0 to 20 for scalp psoriasis, with a score of 0 indicating absence of psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the scalp component of the B-SNIPI among participants with Baseline scalp score of ≥ 6.

Time frame:
Baseline, Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 260.458.3
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = 0.002 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 57.9 · 95% CI 33.8 to 82.0
SecondaryPercentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail bed component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail bed component of "moderate" or "worse."

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Bed Component of the PGA-F at Week 268.251.4
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 43.3 · 95% CI 31.3 to 55.2
SecondaryPercentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 26

The PGA-F is a 5-point scale used to assess fingernails separately for nail bed signs and nail matrix signs of disease. A global score of between 0 indicating clear, and 4 indicating severe, was separately assigned for nail bed involvement and nail matrix involvement. A participant's overall global score was the worse of the nail bed and nail matrix score. Data presents the percentage of participants with a nail matrix component of the PGA-F that met definition of "clear" (0) or "minimal" (1) among those with a Baseline nail matrix component of "moderate" or "worse."

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving "Clear" or "Minimal" in Nail Matrix Component of the PGA-F At Week 268.553.3
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 44.8 · 95% CI 33.2 to 56.5
SecondaryPercentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 261.319.9
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 18.6 · 95% CI 10.6 to 26.6
SecondaryPercentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 267.343.3
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 36.0 · 95% CI 25.0 to 46.9
SecondaryPercentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 260.213.4
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = <0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 13.3 · 95% CI 6.5 to 20.0
SecondaryChange From Baseline in Target Fingernail mNAPSI Score at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Target Fingernail mNAPSI Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Target Fingernail mNAPSI Score at Week 26-2.1 ± 0.27-5.7 ± 0.27
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -3.5 · 95% CI -4.3 to -2.8
SecondaryPercent Change From Baseline in Target Fingernail mNAPSI Score at Week 26

The target fingernail was assessed for psoriasis with mNAPSI. The range of possible scores was 0 to 13, with a score of 0 indicating absence of nail psoriasis and a score of 13 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26-23.0 ± 2.92-61.9 ± 2.91
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -38.9 · 95% CI -46.9 to -30.8
SecondaryChange From Baseline in Total Fingernail mNAPSI Score at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Fingernail mNAPSI Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Total Fingernail mNAPSI Score at Week 26-7.5 ± 1.78-36.1 ± 1.80
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -28.6 · 95% CI -33.5 to -23.7
SecondaryPercent Change From Baseline in Total Fingernail mNAPSI Score at Week 26

Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26-13.2 ± 3.06-63.3 ± 3.02
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -50.1 · 95% CI -58.3 to -41.9
SecondaryPercentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 260.07.5
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = 0.004 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 7.4 · 95% CI 2.4 to 12.4
SecondaryPercentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 262.420.8
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 18.5 · 95% CI 10.1 to 26.8
SecondaryChange From Baseline in Target Fingernail NAPSI Score at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Target Fingernail NAPSI Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Target Fingernail NAPSI Score at Week 26-1.1 ± 0.21-3.6 ± 0.21
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -2.5 · 95% CI -3.1 to -1.9
SecondaryPercent Change From Baseline in Target Fingernail NAPSI Score at Week 26

The target fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI. The range of possible scores was 0 to 8, with a score of 0 indicating absence of nail psoriasis and 8 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26-14.4 ± 3.50-54.6 ± 3.47
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -40.2 · 95% CI -50.0 to -30.4
SecondaryChange From Baseline in Total Fingernail NAPSI Score at Week 26

Each fingernail was assessed for nail matrix psoriasis and nail bed psoriasis with NAPSI and the scores of all 10 fingernails were combined. The range of possible scores was 0 to 80, with a score of 0 indicating absence of nail psoriasis and 80 indicating most severe nail psoriasis. A decrease in NAPSI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total Fingernail NAPSI Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Total Fingernail NAPSI Score at Week 26-6.7 ± 1.51-26.2 ± 1.47
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with stratum, Baseline value, and treatment in the model.) · Ls mean difference: -19.5 · 95% CI -23.6 to -15.3
SecondaryChange From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26-0.9 ± 0.70-9.0 ± 0.70
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -8.1 · 95% CI -10.0 to -6.1
SecondaryPercent Change From Baseline in PASI Score at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. A decrease in PASI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in PASI Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in PASI Score at Week 262.4 ± 5.77-68.7 ± 5.70
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -71.2 · 95% CI -87.3 to -55.0
SecondaryPercentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (plaque thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The score ranges from 0 to 72, with 0 indicating no psoriasis and 72 indicating very severe psoriasis. PASI-75, 50, 90, and 100 responses are the percentage of participants with a Baseline PASI score ≥ 5 who achieved at least a 75%, 50%, 90%, or 100% reduction (improvement), respectively, from Baseline in PASI score at Week 26. A 100% reduction was considered complete clearance of psoriasis. Data presents the percentage of participants achieving PASI 75/50/90/100 responses at Week 26 among participants with a Baseline PASI score ≥ 5.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26
percentage of participantsPlaceboAdalimumab EOW
PASI 7513.864.8
PASI 5025.377.8
PASI 907.148.0
PASI 1002.929.3
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 51.1 · 95% CI 38.6 to 63.5
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 52.5 · 95% CI 39.9 to 65.0
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 40.9 · 95% CI 29.0 to 52.9
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 26.4 · 95% CI 15.8 to 36.9
SecondaryPercentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 26

The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) or "minimal" (1) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) "Clear" or "Minimal" at Week 2611.263.4
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 52.2 · 95% CI 40.8 to 63.7
SecondaryPercentage of Participants Achieving PGA-S of "Clear" at Week 26

The PGA-S is a 6-point scale used to measure the severity of skin disease at the time of the qualified investigator's evaluation of the participant. The degree of overall lesion severity was assessed, with 0 indicating cleared and 5 indicating severe. A decrease in PGA-S score indicates improvement. Data present the percentage of participants achieving a PGA-S of "clear" (0) with at least a 2-grade improvement relative to Baseline at Week 26.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PGA-S of "Clear" at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving PGA-S of "Clear" at Week 264.028.8
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 24.8 · 95% CI 15.3 to 34.3
SecondaryPercentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26

The range of possible B-SNIPI scores was 0 to 20 for inverse psoriasis, with a score of 0 indicating absence of psoriasis and a score of 20 indicating most severe psoriasis. A decrease in B-SNIPI score indicates improvement. Data presents the percentage of participants achieving 50% improvement in the inverse component of the B-SNIPI among participants with a Baseline inverse psoriasis score of ≥ 6.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 260.590.8
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 90.4 · 95% CI 72.5 to 108.3
SecondaryChange From Baseline in Total Body Surface Area (BSA) at Week 26

BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percentage of affected BSA
Change From Baseline in Total Body Surface Area (BSA) at Week 26
percentage of affected BSAPlaceboAdalimumab EOW
Change From Baseline in Total Body Surface Area (BSA) at Week 260.4 ± 1.00-10.7 ± 1.00
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -11.1 · 95% CI -13.9 to -8.4
SecondaryPercent Change From Baseline in Total BSA at Week 26

BSA affected by psoriasis was measured by the physician selecting the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus 5 digits was to be assumed to be approximately equivalent to 1% BSA. Measurement of the total area of involvement by the physician was aided by imagining if scattered plaques were moved so that they were next to each other and then estimated the total area involved. A decrease in BSA affected by psoriasis indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total BSA at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Total BSA at Week 2612.8 ± 6.08-67.8 ± 6.01
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -80.6 · 95% CI -97.9 to -63.3
SecondaryPercent Change From Baseline in Nail Psoriasis Pain NRS at Week 26

An NRS was used to capture a participant's self-reporting of her/his worst fingernail pain and average fingernail pain due to fingernail psoriasis. The participant rated the severity of fingernail pain over the past 7 days on a scale from 0 indicating no pain, to 10 indicating severe pain. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26-18.0 ± 4.80-68.9 ± 4.70
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -50.9 · 95% CI -64.0 to -37.8
SecondaryPercent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26

Participants were asked to rate the impact of their fingernail psoriasis on their ability to perform physical tasks (eg, typing, housework, buttoning a shirt or blouse, picking up coins from a table, tying shoes, yard work, etc.) over the past 7 days on a scale of 0 indicating no impact on ability to perform physical tasks, to 10 indicating severe impact on ability to perform physical tasks. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26-9.9 ± 5.51-67.6 ± 5.63
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -57.7 · 95% CI -73.1 to -42.4
SecondaryChange From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26

Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26-0.4 ± 0.07-1.3 ± 0.07
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
SecondaryPercent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26

Participants rated specific impacts of fingernail psoriasis on various aspects of their QoL over the past 7 days on a 5-point scale, with 0 indicating not at all, and 4 indicating very impactful. A participant's overall global score was the mean of all items and could range from 0 to 4, with 0 indicating no impact and 4 indicating most impact. A decrease in NAPPA QoL score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26
percent changePlaceboAdalimumab EOW
Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26-11.7 ± 2.24-39.5 ± 2.23
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -27.7 · 95% CI -33.9 to -21.6
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26

Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26-1.9 ± 0.60-8.0 ± 0.60
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -6.1 · 95% CI -7.8 to -4.5
SecondaryPercentage of Participants Achieving DLQI of 0 and 0/1 at Week 26

Participants assessed symptoms and impacts of dermatologic diseases on their QoL over the past 7 days, with 0 indicating not at all, and 3 indicating very much. The range of possible DLQI scores was 0 to 30, with a score of 0 indicating no effect at all on a participant's life and a score of 30 indicating extremely large effect on participant's life. A decrease in DLQI score indicates improvement. Data presents the percentage of participants with a score of 0 (no effect) or 1 (little effect) at Week 26.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26
percentage of participantsPlaceboAdalimumab EOW
DLQI = 02.518.2
DLQI = 0/13.730.8
Statistical analysis
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 15.7 · 95% CI 7.1 to 24.3
  • Placebo vs Adalimumab EOW · Cochran-Mantel-Haenszel · p = < 0.001 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 27.1 · 95% CI 16.7 to 37.4
SecondaryChange From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26

The WPAI: NPSO assessed impact of fingernail psoriasis on work productivity and non-work activity limitation. Participants were asked during the past 7 days, how many hours did you miss from work because of problems associated with your fingernail psoriasis (absenteeism), during the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study (presenteeism), how much did your fingernail psoriasis affect your productivity while you were working (overall work impairment), and much did your fingernail psoriasis affect your ability to do your regular daily activities, other than work at a job (activity impairment). Answers were rated on an 11-point scale, with 0 indicating "fingernail psoriasis had no effect on this" and 10 indicating "fingernail psoriasis completely prevented me from this." A decrease in the WPAI:NPSO score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26
units on a scalePlaceboAdalimumab EOW
Absenteeism; n=65, 74-1.0 ± 0.73-0.3 ± 0.65
Presenteeism; n=70, 77-3.4 ± 2.08-20.7 ± 2.06
Overall Work impairment; n=65, 74-6.2 ± 2.20-21.3 ± 2.05
Activity impairment; n=106, 108-1.8 ± 2.09-23.1 ± 2.18
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = 0.416 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: 0.7 · 95% CI -1.0 to 2.5
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -17.3 · 95% CI -22.9 to -11.6
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -15.2 · 95% CI -21.0 to -9.3
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (Across all strata, P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -21.4 · 95% CI -27.3 to -15.4
SecondaryChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26

The EQ-5D-5L descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the subject's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 260.0 ± 0.010.1 ± 0.01
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: 0.1 · 95% CI 0.1 to 0.2
SecondaryChange From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26

The EQ-5D VAS records the participant's self-rated health status on a vertical graduated scale from 0 to 100, with 0 indicating the worst imaginable health state and 100 indicating the best imaginable health state. An increase in EQ-5D-5L VAS score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26-0.1 ± 1.535.5 ± 1.53
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = 0.012 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: 5.5 · 95% CI 1.2 to 9.8
SecondaryChange From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26

Participants rated their anxiety and depression over the past 7 days at Week 26. The range of possible scores was 0 to 21, with a score of 0 indicating absence of anxiety and depression and 21 indicating the most severe anxiety and depression. A decrease in HADS score indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26
units on a scalePlaceboAdalimumab EOW
HADS anxiety score; n=106, 109-0.1 ± 0.33-1.1 ± 0.33
HADS depression score; n=106, 1080.0 ± 0.33-1.4 ± 0.32
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = 0.025 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -1.1 · 95% CI -2.0 to -0.1
  • Placebo vs Adalimumab EOW · ANCOVA · p = 0.005 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -1.3 · 95% CI -2.3 to -0.4
SecondaryPercentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study

The percentage of participants with a new diagnosis of PsA (ie, with an adverse event of PsA) during the study, among participants without PsA at Baseline.

Time frame:
up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study
percentage of participantsPlaceboAdalimumab EOW
Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study02
Statistical analysis
  • Placebo vs Adalimumab EOW · Chi-squared · p = 0.164 (Cochran-Mantel-Haenszel test adjusted for strata. If zero frequency occurred, strata were dropped and p-value was calculated based on chi-square test (or adjusted chi-square test based on Campbell \[2007\]).) · Difference in percentage: 2.5 · 95% CI -0.9 to 6
SecondaryChange From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26

Participants were asked how their fingernail psoriasis impacted their overall quality of life over the past 7 days on an 11-point scale, with 0 indicating no impact, and 10 indicating severe impact. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26
units on a scalePlaceboAdalimumab EOW
Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26-0.6 ± 0.23-3.3 ± 0.23
Statistical analysis
  • Placebo vs Adalimumab EOW · ANCOVA · p = < 0.001 (P values were calculated from ANCOVA with treatment center stratum, Baseline value, and treatment in the model.) · Ls mean difference: -2.8 · 95% CI -3.4 to -2.1

Adverse events

Collected over Adverse events were collected from Baseline through Week 52 +70 day follow up phone call; serious adverse events were collected from Screening through Week 52 + 70 day follow up call.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Period A)—5/108 (4.6%)43/108 (39.8%)
Adalimumab EOW (Period A)—8/109 (7.3%)45/109 (41.3%)
Placebo/Adalimumab EOW (Period B)—3/94 (3.2%)28/94 (29.8%)
Adalimumab EOW/Adalimumab EOW (Period B)—3/94 (3.2%)34/94 (36.2%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlacebo (Period A)Adalimumab EOW (Period A)Placebo/Adalimumab EOW (Period B)Adalimumab EOW/Adalimumab EOW (Period B)
PNEUMONIAInfections and infestations2/1080/1090/941/94
MYOCARDIAL INFARCTIONCardiac disorders0/1080/1091/940/94
DIVERTICULITISInfections and infestations0/1081/1091/940/94
INFLUENZAInfections and infestations0/1080/1090/941/94
LUNG INFECTIONInfections and infestations0/1080/1091/940/94
TENOSYNOVITISMusculoskeletal and connective tissue disorders0/1080/1090/941/94
SEIZURENervous system disorders0/1080/1090/941/94
BLADDER SPHINCTER ATONYRenal and urinary disorders0/1080/1090/941/94
STRESS URINARY INCONTINENCERenal and urinary disorders0/1080/1090/941/94
ATRIAL FIBRILLATIONCardiac disorders1/1080/1090/940/94
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlacebo (Period A)Adalimumab EOW (Period A)Placebo/Adalimumab EOW (Period B)Adalimumab EOW/Adalimumab EOW (Period B)
NASOPHARYNGITISInfections and infestations10/1086/1099/9412/94
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations9/1089/1096/944/94
PSORIASISSkin and subcutaneous tissue disorders6/1081/1094/941/94
HEADACHENervous system disorders0/1086/1092/941/94
ARTHRALGIAMusculoskeletal and connective tissue disorders4/1085/1090/941/94
BACK PAINMusculoskeletal and connective tissue disorders4/1082/1091/942/94
GASTROENTERITISInfections and infestations1/1084/1093/942/94
HYPERTENSIONVascular disorders2/1084/1090/941/94
TOOTHACHEGastrointestinal disorders0/1080/1090/943/94
BRONCHITISInfections and infestations0/1082/1093/942/94

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAdalimumab EOWTotal
Mean46.16 ± 12.13447.21 ± 11.85846.69 ± 11.980
Age, Customized
Age, Customized(participants)PlaceboAdalimumab EOWTotal
< 40 years343064
40 to ≤ 64 years6570135
≥ 65 years9918
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAdalimumab EOWTotal
Female211334
Male8796183
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Oct 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2013
First posted
Dec 20, 2013
Start
Jan 2014
Primary completionActual
Oct 2015
CompletionActual
Apr 2016
Results first posted
Feb 13, 2017
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02016482
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 20, 2013
Start date
Jan 2014
Primary completion
Oct 2015
Completion
Apr 2016
Results posted
Feb 13, 2017
Last update
May 30, 2017

Study contacts

David Williams, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion